Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
10.12997/jla.2019.8.2.242
- Author:
Sang Hak LEE
1
;
Woo Hyuk SONG
;
Myung Ho JEONG
;
Seung Ho HUR
;
Dong Woon JEON
;
Wonju JEUNG
;
Anselm K GITT
;
Martin HORACK
;
Ami VYAS
;
Dominik LAUTSCH
;
Baishali AMBEGAONKAR
;
Philippe BRUDI
;
Yangsoo JANG
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. jangys1212@yuhs.ac
- Publication Type:Original Article
- Keywords:
Cholesterol;
Hydroxymethylglutaryl-CoA reductase inhibitors;
Acute coronary syndrome;
Coronary artery disease;
Dyslipidemias
- MeSH:
Acute Coronary Syndrome;
Cholesterol;
Cohort Studies;
Coronary Artery Disease;
Coronary Vessels;
Dyslipidemias;
Follow-Up Studies;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Korea;
Observational Study
- From:Journal of Lipid and Atherosclerosis
2019;8(2):242-251
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of this study was to evaluate under target rates of low-density lipoprotein-cholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice. METHODS: Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended. Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target. RESULTS: A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%. CONCLUSION: Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients. These results indicate a considerable LLT gap in Korean patients with established CAD.
